FULC's Quality Score fell 1 point on Tue, Nov 10, to -2. It did not trade higher than the day before.
Follow FULC's news. Pro members can get an alert when Fulcrum Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 10% over three years while the S&P 500 rose 80%.
| Since its 2022 high | Down 85% |
| Latest filing | 10-Q, Jul 30 |
ReportExpected to report Monday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It fell after 3 of its last 3 reports, -9.7% on average. Past reports ›
After its last 3 reports it closed -9.7% on average, higher 0 of 3 times.
The company says its cash lasts into 2029 (8-K, Aug 17).
Director Alan Ezekowitz sold 18,000 shares on Jun 26. 2 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
FULC is #168 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 168 |
Expected to report Mon Nov 16, before the open (in 6 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease of $19.0 million was primarily due to cash used to fund operating activities in 2026.”
FULC's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase of $0.7 million was primarily due to higher employee compensation costs, including $0.4 million of increased stock-based compensation expense.”
From its results filing (SEC filing · Apr 27)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Apr 27, 2026 | -4.5% | -1.5% | -6.1% |
| Feb 24, 2026 | -11.4% | -21.2% | -28.3% |
| Oct 29, 2025 | -2.8% | -6.4% | -16.3% |
Sales grew in two of the last five years, to $0 in 2025. It lost money in each of the six years.
RSI 50.4, MACD above signal, below both averages. Not scored.
One insider bought $1.5M across 6 filings, and one insider sold $66K across 1 filing, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: FULC is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
FULC scores -2 today, which Breakaway calls Poor. It is #168 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 10% over three years while the S&P 500 rose 80%. Shares: 22.0% more than a year ago (to Dec 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
FULC scores -2 today, which Breakaway calls Poor (below zero). That is #168 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind FULC's -2.
One insider bought $1.5M across 6 filings, and one insider sold $66K across 1 filing, in the last 6 months. The newest is Kevin Tang, 10% owner, who bought $415K on Jul 16. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.